Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Tipo de estudio
Intervalo de año de publicación
1.
PLoS Pathog ; 9(10): e1003662, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24204255

RESUMEN

In this study, B cell function in protective T(H)2 immunity against N. brasiliensis infection was investigated. Protection against secondary infection depended on IL-4Rα and IL-13; but not IL-4. Protection did not associate with parasite specific antibody responses. Re-infection of B cell-specific IL-4Rα⁻/⁻ mice resulted in increased worm burdens compared to control mice, despite their equivalent capacity to control primary infection. Impaired protection correlated with reduced lymphocyte IL-13 production and B cell MHC class II and CD86 surface expression. Adoptive transfer of in vivo N. brasiliensis primed IL-4Rα expressing B cells into naïve BALB/c mice, but not IL-4Rα or IL-13 deficient B cells, conferred protection against primary N. brasiliensis infection. This protection required MHC class II compatibility on B cells suggesting cognate interactions by B cells with CD4⁺ T cells were important to co-ordinate immunity. Furthermore, the rapid nature of these protective effects by B cells suggested non-BCR mediated mechanisms, such as via Toll Like Receptors, was involved, and this was supported by transfer experiments using antigen pulsed Myd88⁻/⁻ B cells. These data suggest TLR dependent antigen processing by IL-4Rα-responsive B cells producing IL-13 contribute significantly to CD4⁺ T cell-mediated protective immunity against N. brasiliensis infection.


Asunto(s)
Presentación de Antígeno , Linfocitos B/inmunología , Inmunidad Celular , Nippostrongylus/inmunología , Receptores de Superficie Celular/inmunología , Infecciones por Strongylida/inmunología , Células Th2/inmunología , Animales , Linfocitos B/patología , Antígeno B7-2/genética , Antígeno B7-2/inmunología , Antígenos de Histocompatibilidad Clase II/genética , Antígenos de Histocompatibilidad Clase II/inmunología , Interleucina-13/genética , Interleucina-13/inmunología , Ratones Endogámicos BALB C , Ratones Noqueados , Factor 88 de Diferenciación Mieloide/genética , Factor 88 de Diferenciación Mieloide/inmunología , Receptores de Superficie Celular/genética , Infecciones por Strongylida/genética , Infecciones por Strongylida/patología , Células Th2/patología , Receptores Toll-Like/genética , Receptores Toll-Like/inmunología
2.
PLoS Negl Trop Dis ; 6(3): e1564, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22428079

RESUMEN

The large extracellular loop of the Schistosoma mansoni tetraspanin, Sm-TSP-2, when fused to a thioredoxin partner and formulated with Freund's adjuvants, has been shown to be an efficacious vaccine against murine schistosomiasis. Moreover, Sm-TSP-2 is uniquely recognised by IgG(1) and IgG(3) from putatively resistant individuals resident in S. mansoni endemic areas in Brazil. In the present study, we expressed Sm-TSP-2 at high yield and in soluble form in E. coli without the need for a solubility enhancing fusion partner. We also expressed in E. coli a chimera called Sm-TSP-2/5B, which consisted of Sm-TSP-2 fused to the immunogenic 5B region of the hookworm aspartic protease and vaccine antigen, Na-APR-1. Sm-TSP-2 formulated with alum/CpG showed significant reductions in adult worm and liver egg burdens in two separate murine schistosomiasis challenge studies. Sm-TSP-2/5B afforded significantly greater protection than Sm-TSP-2 alone when both antigens were formulated with alum/CpG. The enhanced protection obtained with the chimeric fusion protein was associated with increased production of anti-Sm-TSP-2 antibodies and IL-4, IL-10 and IFN-γ from spleen cells of vaccinated animals. Sera from 666 individuals from Brazil who were infected with S. mansoni were screened for potentially deleterious IgE responses to Sm-TSP-2. Anti-Sm-TSP-2 IgE to this protein was not detected (also shown previously for Na-APR-1), suggesting that the chimeric antigen Sm-TSP-2/5B could be used to safely and effectively vaccinate people in areas where schistosomes and hookworms are endemic.


Asunto(s)
Antígenos Helmínticos/inmunología , Esquistosomiasis/prevención & control , Tetraspaninas/inmunología , Adyuvantes Inmunológicos/administración & dosificación , Adolescente , Adulto , Anciano , Compuestos de Alumbre/administración & dosificación , Animales , Anticuerpos Antihelmínticos/sangre , Antígenos Helmínticos/administración & dosificación , Antígenos Helmínticos/genética , Proteasas de Ácido Aspártico/administración & dosificación , Proteasas de Ácido Aspártico/genética , Proteasas de Ácido Aspártico/inmunología , Brasil , Niño , Preescolar , Citocinas/metabolismo , Modelos Animales de Enfermedad , Escherichia coli/genética , Femenino , Expresión Génica , Humanos , Inmunoglobulina G/sangre , Lactante , Leucocitos Mononucleares/inmunología , Masculino , Ratones , Ratones Endogámicos C57BL , Persona de Mediana Edad , Oligodesoxirribonucleótidos/administración & dosificación , Proteínas Recombinantes de Fusión/administración & dosificación , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/inmunología , Esquistosomiasis/inmunología , Bazo/inmunología , Tetraspaninas/administración & dosificación , Tetraspaninas/genética , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/inmunología , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA